Research Associate
![]() | |
![]() United States, Ohio, Columbus | |
![]() 281 West Lane Avenue (Show on map) | |
![]() | |
The laboratory of Dr. Eric Greidinger, Associate Director of the Center for Innate Immunity and Inflammation, studies how innate immunity including STING signaling influence the development and tissue targeting of autoimmune diseases, to develop better therapies for these conditions. He is also investigating the development of anti-self responses in cancer, both to understand and treat paraneoplastic autoimmune conditions and to develop new approaches to cancer therapy. This work seeks to develop novel treatments for diseases for which effective treatments are not currently available. The Greidinger Lab, working closely with the laboratory of Dr. Glen Barber, Director of the Center for Innate Immunity and Inflammation, is seeking a Research Associate to provide administrative and technical support for this research. The Research Associate will perform the following:
Minimum Qualifications Bachelor's Degree or equivalent experience required; 1 year of relevant experience required with a Bachelor's Degree . Preferred: Master's degree or greater in an appropriate biological/health science or at least 4 years lab work experience.
Function: Research and Scholarship Sub Function: Research Career Band: Individual Contributor - Specialized Career Level: S1 The OSUCCC features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic medical center and a freestanding cancer hospital on the campus of one of the nations largest public universities. The OSUCCC James Pelotonia Institute for Immuno-Oncology (PIIO) is a comprehensive bench-to-bedside research initiative focused on harnessing the bodys immune system to fight cancer at all levels from prevention to treatment and survivorship. The Center for Innate Immunity and Inflammation within the OSUCCC-PIIO is taking novel approaches to harness (or restrain) immunity and inflammation in translational approaches at the intersection of oncology and autoimmunity. |